PHIBRO ANIMAL HEALTH CORP-A (PAHC) Stock Fundamental Analysis

NASDAQ:PAHC • US71742Q1067

52.26 USD
+0.99 (+1.94%)
At close: Feb 13, 2026
52.26 USD
0 (0%)
After Hours: 2/13/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

Taking everything into account, PAHC scores 6 out of 10 in our fundamental rating. PAHC was compared to 191 industry peers in the Pharmaceuticals industry. PAHC scores excellent on profitability, but there are some minor concerns on its financial health. PAHC is valued quite cheap, while showing a decent growth score. This is a good combination! With these ratings, PAHC could be worth investigating further for value investing!.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year PAHC was profitable.
  • In the past year PAHC had a positive cash flow from operations.
  • Each year in the past 5 years PAHC has been profitable.
  • Each year in the past 5 years PAHC had a positive operating cash flow.
PAHC Yearly Net Income VS EBIT VS OCF VS FCFPAHC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M

1.2 Ratios

  • PAHC's Return On Assets of 6.55% is amongst the best of the industry. PAHC outperforms 87.96% of its industry peers.
  • PAHC has a better Return On Equity (27.71%) than 93.19% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 13.16%, PAHC belongs to the top of the industry, outperforming 92.15% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for PAHC is below the industry average of 12.64%.
  • The 3 year average ROIC (8.29%) for PAHC is below the current ROIC(13.16%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.55%
ROE 27.71%
ROIC 13.16%
ROA(3y)2.38%
ROA(5y)3.78%
ROE(3y)9.79%
ROE(5y)14.19%
ROIC(3y)8.29%
ROIC(5y)8.41%
PAHC Yearly ROA, ROE, ROICPAHC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

1.3 Margins

  • Looking at the Profit Margin, with a value of 6.29%, PAHC belongs to the top of the industry, outperforming 81.68% of the companies in the same industry.
  • In the last couple of years the Profit Margin of PAHC has declined.
  • The Operating Margin of PAHC (12.78%) is better than 85.86% of its industry peers.
  • In the last couple of years the Operating Margin of PAHC has grown nicely.
  • PAHC has a Gross Margin (32.56%) which is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of PAHC has remained more or less at the same level.
Industry RankSector Rank
OM 12.78%
PM (TTM) 6.29%
GM 32.56%
OM growth 3Y8.12%
OM growth 5Y4.74%
PM growth 3Y-10.66%
PM growth 5Y-2.37%
GM growth 3Y1.41%
GM growth 5Y-0.32%
PAHC Yearly Profit, Operating, Gross MarginsPAHC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), PAHC is creating some value.
  • The number of shares outstanding for PAHC remains at a similar level compared to 1 year ago.
  • PAHC has about the same amout of shares outstanding than it did 5 years ago.
  • The debt/assets ratio for PAHC is higher compared to a year ago.
PAHC Yearly Shares OutstandingPAHC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
PAHC Yearly Total Debt VS Total AssetsPAHC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • PAHC has an Altman-Z score of 3.48. This indicates that PAHC is financially healthy and has little risk of bankruptcy at the moment.
  • With a decent Altman-Z score value of 3.48, PAHC is doing good in the industry, outperforming 68.06% of the companies in the same industry.
  • PAHC has a debt to FCF ratio of 15.46. This is a negative value and a sign of low solvency as PAHC would need 15.46 years to pay back of all of its debts.
  • The Debt to FCF ratio of PAHC (15.46) is better than 76.96% of its industry peers.
  • PAHC has a Debt/Equity ratio of 2.14. This is a high value indicating a heavy dependency on external financing.
  • PAHC has a Debt to Equity ratio of 2.14. This is in the lower half of the industry: PAHC underperforms 79.06% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.14
Debt/FCF 15.46
Altman-Z 3.48
ROIC/WACC1.46
WACC9.02%
PAHC Yearly LT Debt VS Equity VS FCFPAHC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • PAHC has a Current Ratio of 3.05. This indicates that PAHC is financially healthy and has no problem in meeting its short term obligations.
  • PAHC has a Current ratio (3.05) which is comparable to the rest of the industry.
  • PAHC has a Quick Ratio of 1.22. This is a normal value and indicates that PAHC is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.22, PAHC is doing worse than 72.25% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.05
Quick Ratio 1.22
PAHC Yearly Current Assets VS Current LiabilitesPAHC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 73.91% over the past year.
  • The Earnings Per Share has been growing by 14.12% on average over the past years. This is quite good.
  • The Revenue has grown by 32.39% in the past year. This is a very strong growth!
  • Measured over the past years, PAHC shows a quite strong growth in Revenue. The Revenue has been growing by 10.12% on average per year.
EPS 1Y (TTM)73.91%
EPS 3Y19.98%
EPS 5Y14.12%
EPS Q2Q%61.11%
Revenue 1Y (TTM)32.39%
Revenue growth 3Y11.21%
Revenue growth 5Y10.12%
Sales Q2Q%20.89%

3.2 Future

  • PAHC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.77% yearly.
  • PAHC is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -2.45% yearly.
EPS Next Y33.72%
EPS Next 2Y21.35%
EPS Next 3Y17.77%
EPS Next 5YN/A
Revenue Next Year14.65%
Revenue Next 2Y8.81%
Revenue Next 3Y6.86%
Revenue Next 5Y-2.45%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
PAHC Yearly Revenue VS EstimatesPAHC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 500M 1B 1.5B
PAHC Yearly EPS VS EstimatesPAHC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • PAHC is valuated rather expensively with a Price/Earnings ratio of 18.66.
  • PAHC's Price/Earnings ratio is rather cheap when compared to the industry. PAHC is cheaper than 84.29% of the companies in the same industry.
  • PAHC is valuated rather cheaply when we compare the Price/Earnings ratio to 27.19, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 16.98, the valuation of PAHC can be described as correct.
  • Based on the Price/Forward Earnings ratio, PAHC is valued cheaper than 81.68% of the companies in the same industry.
  • PAHC is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 18.66
Fwd PE 16.98
PAHC Price Earnings VS Forward Price EarningsPAHC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PAHC is valued cheaper than 86.39% of the companies in the same industry.
  • 78.53% of the companies in the same industry are more expensive than PAHC, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 44.79
EV/EBITDA 11.59
PAHC Per share dataPAHC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

  • PAHC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • PAHC has an outstanding profitability rating, which may justify a higher PE ratio.
  • PAHC's earnings are expected to grow with 17.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.55
PEG (5Y)1.32
EPS Next 2Y21.35%
EPS Next 3Y17.77%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. Dividend

5.1 Amount

  • With a yearly dividend of 0.94%, PAHC is not a good candidate for dividend investing.
  • PAHC's Dividend Yield is rather good when compared to the industry average which is at 1.18. PAHC pays more dividend than 90.05% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, PAHC's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.94%

5.2 History

  • The dividend of PAHC has a limited annual growth rate of 0.02%.
  • PAHC has paid a dividend for at least 10 years, which is a reliable track record.
  • PAHC has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)0.02%
Div Incr Years0
Div Non Decr Years10
PAHC Yearly Dividends per sharePAHC Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.1 0.2 0.3 0.4

5.3 Sustainability

  • 21.13% of the earnings are spent on dividend by PAHC. This is a low number and sustainable payout ratio.
  • The dividend of PAHC is growing, but earnings are growing more, so the dividend growth is sustainable.
DP21.13%
EPS Next 2Y21.35%
EPS Next 3Y17.77%
PAHC Yearly Income VS Free CF VS DividendPAHC Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M 80M
PAHC Dividend Payout.PAHC Dividend Payout, showing the Payout Ratio.PAHC Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

PHIBRO ANIMAL HEALTH CORP-A

NASDAQ:PAHC (2/13/2026, 8:00:02 PM)

After market: 52.26 0 (0%)

52.26

+0.99 (+1.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-04
Earnings (Next)05-05
Inst Owners100.08%
Inst Owner Change-6.44%
Ins Owners0.52%
Ins Owner Change11.65%
Market Cap2.12B
Revenue(TTM)1.46B
Net Income(TTM)92.09M
Analysts48.89
Price Target43.86 (-16.07%)
Short Float %5.15%
Short Ratio3.91
Dividend
Industry RankSector Rank
Dividend Yield 0.94%
Yearly Dividend0.48
Dividend Growth(5Y)0.02%
DP21.13%
Div Incr Years0
Div Non Decr Years10
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.14%
Min EPS beat(2)14.97%
Max EPS beat(2)27.3%
EPS beat(4)4
Avg EPS beat(4)17.13%
Min EPS beat(4)7.47%
Max EPS beat(4)27.3%
EPS beat(8)8
Avg EPS beat(8)19.67%
EPS beat(12)9
Avg EPS beat(12)9.55%
EPS beat(16)10
Avg EPS beat(16)3.77%
Revenue beat(2)2
Avg Revenue beat(2)2.95%
Min Revenue beat(2)2.82%
Max Revenue beat(2)3.07%
Revenue beat(4)3
Avg Revenue beat(4)1.29%
Min Revenue beat(4)-3.24%
Max Revenue beat(4)3.07%
Revenue beat(8)6
Avg Revenue beat(8)1.55%
Revenue beat(12)7
Avg Revenue beat(12)0.18%
Revenue beat(16)10
Avg Revenue beat(16)0.46%
PT rev (1m)0%
PT rev (3m)31.63%
EPS NQ rev (1m)4.78%
EPS NQ rev (3m)2.89%
EPS NY rev (1m)0%
EPS NY rev (3m)4.08%
Revenue NQ rev (1m)0.34%
Revenue NQ rev (3m)0.34%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.47%
Valuation
Industry RankSector Rank
PE 18.66
Fwd PE 16.98
P/S 1.45
P/FCF 44.79
P/OCF 22.76
P/B 6.37
P/tB 8.84
EV/EBITDA 11.59
EPS(TTM)2.8
EY5.36%
EPS(NY)3.08
Fwd EY5.89%
FCF(TTM)1.17
FCFY2.23%
OCF(TTM)2.3
OCFY4.39%
SpS36.13
BVpS8.2
TBVpS5.91
PEG (NY)0.55
PEG (5Y)1.32
Graham Number22.73
Profitability
Industry RankSector Rank
ROA 6.55%
ROE 27.71%
ROCE 16.66%
ROIC 13.16%
ROICexc 14.09%
ROICexgc 15.46%
OM 12.78%
PM (TTM) 6.29%
GM 32.56%
FCFM 3.23%
ROA(3y)2.38%
ROA(5y)3.78%
ROE(3y)9.79%
ROE(5y)14.19%
ROIC(3y)8.29%
ROIC(5y)8.41%
ROICexc(3y)9.26%
ROICexc(5y)9.5%
ROICexgc(3y)10.65%
ROICexgc(5y)11.26%
ROCE(3y)10.49%
ROCE(5y)10.64%
ROICexgc growth 3Y1.17%
ROICexgc growth 5Y-1.23%
ROICexc growth 3Y4.48%
ROICexc growth 5Y1.99%
OM growth 3Y8.12%
OM growth 5Y4.74%
PM growth 3Y-10.66%
PM growth 5Y-2.37%
GM growth 3Y1.41%
GM growth 5Y-0.32%
F-Score7
Asset Turnover1.04
Health
Industry RankSector Rank
Debt/Equity 2.14
Debt/FCF 15.46
Debt/EBITDA 2.99
Cap/Depr 90.23%
Cap/Sales 3.13%
Interest Coverage 250
Cash Conversion 39.13%
Profit Quality 51.35%
Current Ratio 3.05
Quick Ratio 1.22
Altman-Z 3.48
F-Score7
WACC9.02%
ROIC/WACC1.46
Cap/Depr(3y)116.74%
Cap/Depr(5y)111.08%
Cap/Sales(3y)4.1%
Cap/Sales(5y)3.95%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)73.91%
EPS 3Y19.98%
EPS 5Y14.12%
EPS Q2Q%61.11%
EPS Next Y33.72%
EPS Next 2Y21.35%
EPS Next 3Y17.77%
EPS Next 5YN/A
Revenue 1Y (TTM)32.39%
Revenue growth 3Y11.21%
Revenue growth 5Y10.12%
Sales Q2Q%20.89%
Revenue Next Year14.65%
Revenue Next 2Y8.81%
Revenue Next 3Y6.86%
Revenue Next 5Y-2.45%
EBIT growth 1Y82.86%
EBIT growth 3Y20.25%
EBIT growth 5Y15.34%
EBIT Next Year75.33%
EBIT Next 3Y25.44%
EBIT Next 5Y2.18%
FCF growth 1Y27.7%
FCF growth 3YN/A
FCF growth 5Y10.58%
OCF growth 1Y25.35%
OCF growth 3Y36.29%
OCF growth 5Y6.19%

PHIBRO ANIMAL HEALTH CORP-A / PAHC FAQ

Can you provide the ChartMill fundamental rating for PHIBRO ANIMAL HEALTH CORP-A?

ChartMill assigns a fundamental rating of 6 / 10 to PAHC.


What is the valuation status of PHIBRO ANIMAL HEALTH CORP-A (PAHC) stock?

ChartMill assigns a valuation rating of 7 / 10 to PHIBRO ANIMAL HEALTH CORP-A (PAHC). This can be considered as Undervalued.


Can you provide the profitability details for PHIBRO ANIMAL HEALTH CORP-A?

PHIBRO ANIMAL HEALTH CORP-A (PAHC) has a profitability rating of 8 / 10.


What is the financial health of PHIBRO ANIMAL HEALTH CORP-A (PAHC) stock?

The financial health rating of PHIBRO ANIMAL HEALTH CORP-A (PAHC) is 5 / 10.


What is the expected EPS growth for PHIBRO ANIMAL HEALTH CORP-A (PAHC) stock?

The Earnings per Share (EPS) of PHIBRO ANIMAL HEALTH CORP-A (PAHC) is expected to grow by 33.72% in the next year.